ROCKVILLE, MD, USA I May 13, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the ...

Expect to report topline data from the Seabreeze STAT Asthma study in 1H 2026 – – On track to initiate similarly-designed Phase 2 study in patients with COPD imminently S ...

WALTHAM, MA, USA I May 12, 2025 I Invivyd, Inc. (Nasdaq: IVVD) today announced it has initiated a discovery program for a measles monoclonal antibody (mAb).

LONDON, UK I May 12, 2025 I Leucid Bio ("Leucid" or "The Company"), a privately-held biotechnology company pursuing the development of innovative Chimeric ...

SHANGHAI, China I May 11, 2025 I CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, ...

The RENEW Phase 2 trial will enroll up to 120 IPF patients with topline data expected in the first half of 2026 ...

HT-KIT is engineered to selectively bind to mutant KIT mRNA transcripts and block their translation, thereby preventing the production of the KIT protein, a critical driver of tumor growth in cancers ...

CAP-002 is the first engineered IV-delivered gene therapy that crosses the blood-brain-barrier and detargets the liver and dorsal root ganglia to enter the ...

VANCOUVER, Canada I May 09, 2025 I AbCellera (Nasdaq: ABCL) today announced preclinical data on ABCL575, which will be presented as a poster at the Society ...

New breakthrough data from studies with Coave’s ALIGATER™-engineered AAV2-based capsid coAAV-CSF-01 (S01coAAV2) demonstrates improved brain tissue ...

66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to ...

SHANGHAI, China I May 9, 2025 I Minghui Pharmaceutical (“Minghui”), a late-stage clinical biopharmaceutical company, today announced an exclusive licensing and collaboration agreement with Qilu ...